Regulatory T cells, tumour immunity and immunotherapy
Explore this paper's citation graph
Summary
The nature and characteristics of regulatory T cells in the tumour microenvironment and their potential multiple suppressive mechanisms are considered.
- Type
- review
- Published
- 2006-04-01
- Cited by
- 2,207
- References
- 162
- Access
- Open access
- OpenAlex
- https://openalex.org/W2073310925
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:31200544
Keywords
Immunotherapy, Antigen, Immunology, Immunity, Biology
References
- Regulatory lymphocytes: Antigen-induced regulatory T cells in autoimmunity
- Interleukin‐2 is essential for CD4+CD25+ regulatory T cell function
- Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivo
- Dendritic Cells Loaded with Stressed Tumor Cells Elicit Long-Lasting Protective Tumor Immunity in Mice Depleted of CD4+CD25+ Regulatory T Cells1
- Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumour. Evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden.
- Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor L3T4+ suppressor T-cells.
- Tolerogenic Semimature Dendritic Cells Suppress Experimental Autoimmune Thyroiditis by Activation of Thyroglobulin-Specific CD4+CD25+ T Cells1
- CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies
- A CD4+T-cell subset inhibits antigen-specific T-cell responses and prevents colitis
- Infectious immunological tolerance.
- CD4+CD25+ suppressor T cells: more questions than answers
- Response to Comment on “Cutting Edge: Induction of B7-H4 on APCs through IL-10: Novel Suppressive Mode for Regulatory T Cells”
- Cutting Edge: Contact-Mediated Suppression by CD4+CD25+ Regulatory Cells Involves a Granzyme B-Dependent, Perforin-Independent Mechanism1
- Immune response to syngeneic or autologous testicular cells in mice. I. Augmented delayed footpad reaction in cyclophosphamide-treated mice.
- Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells
- Cell interactions in the induction of tolerance: the role of thymic lymphocytes.
- CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers.
- Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-beta.
- Cutting Edge: TGF-β Induces a Regulatory Phenotype in CD4+CD25− T Cells through Foxp3 Induction and Down-Regulation of Smad7
- CD4+/CD25+ Regulatory Cells Inhibit Activation of Tumor-Primed CD4+ T Cells with IFN-γ-Dependent Antiangiogenic Activity, as well as Long-Lasting Tumor Immunity Elicited by Peptide Vaccination 1
Cited by
- Immune based therapies in cancer.
- OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection
- A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells.
- Regulatory T cells: a new frontier in cancer immunotherapy.
- Basic Science Review: Nitric Oxide—Releasing Prosthetic Materials
- Suppressive Influences in the Immune Response to Cancer
- Development of a Cancer Vaccine Targeting Tumor Blood Vessels
- Interleukins 1α and 1β secreted by some melanoma cell lines strongly reduce expression of MITF‐M and melanocyte differentiation antigens
- NF-κB and STAT3 signaling in glioma: targets for future therapies
- Polyclonal expansion of human CD4(+)CD25(+) regulatory T cells.
- Inflammatory Blood Monocytes Contribute to Tumor Development and Represent a Privileged Target To Improve Host Immunosurveillance
- Immunomodulating antibodies and drugs for the treatment of hematological malignancies
- Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus.
- Immunotherapy of prostate cancer: should we be targeting stem cells and EMT?
- Resveratrol analogue HS-1793 induces the modulation of tumor-derived T cells.
- Regulation of COX2 Expression in Mouse Mammary Tumor Cells Controls Bone Metastasis and PGE2-Induction of Regulatory T Cell Migration
- CD40 ligation reverses T cell tolerance in acute myeloid leukemia.
- Cordycepin-enriched Cordyceps militaris induces immunomodulation and tumor growth delay in mouse-derived breast cancer.
- Effects of gastric cancer cells on the differentiation of Treg cells.
- Cancer immunotherapy: accomplishments to date and future promise.
Related papers
- Non‐specific and specific active immunotherapy in a B16 murine melanoma system
- Cancer Immunotherapy and Application of Nanoparticles in Cancers Immunotherapy as the Delivery of Immunotherapeutic Agents and as the Immunomodulators
- pH-Responsive Nanoparticles for Cancer Immunotherapy: A Brief Review
- Triggering Immune System With Nanomaterials for Cancer Immunotherapy
- Cancer Physical Hallmarks as New Targets for Improved Immunotherapy.
- Enhancement of the Expression of Progesterone Receptor on Progesterone‐Treated Lymphocytes After Immunotherapy in Unexplained Recurrent Spontaneous Abortion
- Dendritic cell vaccine and cancer treatment: new patents.